None listed
Conditions
Interventions
Intervention1: Probenecid 500 mg: Probenecid 500 mg, per oral, twice daily for 14 days
Intervention2: Probenecid 1000 mg: Probenecid 1000 mg, per oral, twice daily for 14 days
Control Intervention1: P
Sponsors
Dr Neelam Pandey
Eligibility
Inclusion criteria
Inclusion criteria: 1. Non-hospitalized Patients with RT-PCR confirmed COVID-19 in 2. Patients with WHO Ordinal Scale score 2 and 3. 3. Patient has presented within 5 days or less of randomization with at least one early onset COVID-19 symptom (i.e. fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea, vomiting or diarrhea). 4. Men and non-pregnant women, 18 â?? 65 years of age. 5. Patient has estimated glomerular filtration rate (eGFR) >=30 mL/min using the Cockcroft-Gault formula. 6. Willing to participate in this study, signed Informed Consent and willing to participate in regular follow-up during the study. 7. Able to understand and cooperate with study procedures.
Exclusion criteria
Exclusion criteria: 1. Subjects hospitalized: a. Patients with severe or critical forms of COVID-19 illness or those who are on ventilator support, ECMO, or shock requiring vasopressor support or those with cytokine storm even not in hospital b. Patients hospitalized for treatment of severe illnesses c. â??Long COVID-19â?? syndrome (defined as a diverse set of symptoms that persist after a minimum of 4 weeks from the onset of a diagnosed COVID-19 infection. Common symptoms include respiratory system disorders, nervous system and neurocognitive disorders, mental health disorders, metabolic disorders, cardiovascular disorders, gastrointestinal disorders, malaise, fatigue, musculoskeletal pain, and anemia). 2. Females who are pregnant, breast feeding, or planning a pregnancy. 3. Patients with known blood dyscrasia and uric acid kidney stones 4. Females of childbearing potential who do not agree to utilize an adequate effective form of contraception. 5. Males with partners of child-bearing potential unwilling to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or to sexual abstinence effective from the first administration of any of the IPs throughout the trial. 6. Men with partners of child-bearing potential unwilling to ensure that their partner uses an effective method of contraception for the same duration for example, hormonal contraception, intrauterine device, diaphragm with spermicidal gel, or sexual abstinence. Men with pregnant or lactating partners unwilling to use barrier method contraception (for example, condom plus spermicidal gel) to prevent exposure of the fetus or neonate. 7. Abstinence is only considered to be an acceptable method of contraception when this is in line with the preferred and usual lifestyle of the patients. Periodic abstinence (e.g., calendar, ovulation, sympathothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 8. History of alcohol, chemical, or drug abuse or dependence as per DSM IV criteria within past 6 months. 9. Current active malignancy or history of malignancy within the past five years. 10. Known hypersensitivity history to Investigational Products or any of its component 11. Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to potential severe drug interaction. 12. Patients with the following conditions: a. Immunosuppression b. HIV c. Current neoplasms 13. Has a history of hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, hepatocellular carcinoma. 14. Any other clinically significant abnormal medical condition, which in the Investigatorâ??s judgment, would put the patient at increased risk of illness or injury would interfere with study participation or would interfere with the evaluation or quality of the data. 15. Investigatorâ??s judgment that participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to: participants who are not expected to survive longer than 48 hours after randomization, or participants with a recent history of mechanical ventilation, or participants with conditions that could limit gastrointestinal absorption of capsule contents. 16. Is taking or is anticipated to re
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Time to viral RNA clearance, as measured by quantitative RT-PCR analysis of nasopharyngeal swabs using a validated, laboratory-developed test based on the U.S. Centers for Disease Control and Prevention 2019-nCoV Emergency Use Authorization assay.Timepoint: Day 15 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Reduction in SARS-CoV-2 viral load at Day 3 from BaselineTimepoint: Day 3;10. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Timepoint: Day 15I;11. Incidence of Treatment-Emergent Adverse EventsTimepoint: Day 15;12. All-cause mortalityTimepoint: Day 15;13. Pharmacokinetic profile of Probenecid 500 mg twice daily and 1000mg twice daily.Timepoint: Day 5;2. Reduction in SARS-CoV-2 viral load at Day 5 from BaselineTimepoint: Day 5;3. Reduction in SARS-CoV-2 viral load at Day 10 from BaselineTimepoint: Day 10;4. Reduction in SARS-CoV-2 viral load at Day 15 from BaselineTimepoint: Day 15;5. Proportion of patients with symptoms resolution at Day 3 from BaselineTimepoint: Day 3;6. Proportion of patients with symptoms resolution at Day 10 from BaselineTimepoint: Day 10;7. Proportion of patients with symptoms resolution at Day 15 from BaselineTimepoint: Day 15;8. Proportion of patients requiring hospitalizationTimepoint: Day 15;9. Change in WHO clinical progressions scale at Day 3, 5, 10 and 15 from baselineTimepoint: Day 15 | — |
Countries
India
Contacts
Public ContactDr Neelam Pandey
Consultant Physician
Outcome results
None listed